Impact of covid-19 on long-term oxygen therapy 2020: A nationwide study in Sweden.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
11
2021
accepted:
19
03
2022
entrez:
8
4
2022
pubmed:
9
4
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Covid-19 can cause chronic hypoxic respiratory failure, but the impact on the need for long-term oxygen therapy (LTOT) is unknown. The aim was to investigate change in incidence and characteristics of patients starting LTOT in Sweden 2020 after the outbreak of the pandemic. Population-based observational study using data from the National Registry for Respiratory Failure (Swedevox) and from a survey to all centres prescribing LTOT in Sweden. Swedevox data provided information on incidence of LTOT and characteristics of patients starting LTOT during 2015-2020. Between March-Dec 2020, 131 patients started LTOT due to covid-19, corresponding to 20.5% of incident LTOT in Sweden. Compared with 2015-19, the total number of patients starting LTOT did not increase. No significant differences in patient characteristics or underlying causes of hypoxemia were found between patients starting LTOT during 2020 compared 2015-2019. The majority of the LTOT centres estimated that, since the start of the pandemic, the incidence of LTOT was unchanged and the time devoted for LTOT work was the same or slightly less. Covid-19 caused one fifth of all LTOT starts during the pandemic in 2020. The LTOT incidence overall did not increase possibly due to reduction in other infections.
Identifiants
pubmed: 35395039
doi: 10.1371/journal.pone.0266367
pii: PONE-D-21-37749
pmc: PMC8992997
doi:
Substances chimiques
Oxygen
S88TT14065
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0266367Déclaration de conflit d'intérêts
The authors have no conflicts of interest related to the study.
Références
Ann Intern Med. 1980 Sep;93(3):391-8
pubmed: 6776858
Scand J Public Health. 2021 Nov;49(7):681-688
pubmed: 33764202
J Pain Symptom Manage. 2018 Sep;56(3):430-435.e2
pubmed: 29753099
Respir Med. 2021 Jun;182:106394
pubmed: 33901787
PLoS One. 2021 Aug 3;16(8):e0255659
pubmed: 34343205
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Lancet. 1981 Mar 28;1(8222):681-6
pubmed: 6110912
ERJ Open Res. 2021 Jan 18;7(1):
pubmed: 33532458
BMJ Qual Saf. 2021 Dec;30(12):986-995
pubmed: 33952687
Eur J Radiol. 2021 May;138:109676
pubmed: 33798931
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Respir Med. 2022 Jan;191:106709
pubmed: 34871947
JAMA Netw Open. 2021 Jan 4;4(1):e2036142
pubmed: 33502487
Int J Chron Obstruct Pulmon Dis. 2017 Oct 30;12:3159-3169
pubmed: 29133978
JAMA Intern Med. 2020 Nov 1;180(11):1436-1447
pubmed: 32667668
Lancet Respir Med. 2021 Feb;9(2):139-148
pubmed: 33169671
Thorax. 2015 Jun;70 Suppl 1:i1-43
pubmed: 25870317
Lancet Respir Med. 2021 Apr;9(4):407-418
pubmed: 33460571
Lancet Infect Dis. 2020 Dec;20(12):1365
pubmed: 32530428
Lancet Respir Med. 2020 Sep;8(9):853-862
pubmed: 32735842
Respir Res. 2021 Jan 21;22(1):29
pubmed: 33478527